Cullinan Therapeutics

Our clinical approach centers around an expedited path to clinical proof of concept. In his latest article, Jeff Jones, Chief Medical Officer, dives into our clinical strategy and how it’s applied to the development of CLN-978, our CD19xCD3 bispecific T cell engager, in autoimmune diseases. Click to read the full article. https://bit.ly/3BNN3oy ?

Today, we announced the U.S. FDA has cleared our Investigational New Drug Application for CLN-978 in systemic lupus erythematosus (#SLE). ?CLN-978 is the first development stage CD19 T cell engager to receive IND Clearance in #autoimmune diseases. CLN-978 is a novel bispecific T cell engager that targets CD19, offering a highly differentiated approach to deliver the potency of T cell redirecting therapy with off-the-shelf access and convenient dosing through subcutaneous administration.? We are advancing CLN-978 in our global Phase 1 clinical trial for patients living with SLE.?? Learn more: https://bit.ly/3zX2F8P

While there have been advancements in autoimmune disease research in recent years, there remains a high unmet need for treatment options with potential to deliver durable remissions. We believe collaboration and scientific exchange are critical to advancing new ideas that have a higher chance of benefitting patients. We’re proud to be a sponsor of two upcoming conferences and look forward to engaging with participants from across the globe: ???The 11th International Conference on Autoimmunity? ???The 16th International Forum for Rheumatoid Arthritis (IFRA) On Friday, October 18, at 12:50 p.m. EEST, join Patrick A. Baeuerle, Ph.D., Co-founder and Chief Scientific Advisor, at the 11th International Conference on Autoimmunity for an oral presentation on T cell engagers. Also on Friday, October 18, at 4:45 p.m. CEST, join Ricardo Grieshaber-Bouyer, M.D. Ph.D., Professor of Clinical Systems Immunology and head of the Clinical Trials Unit at FAU Erlangen-Nuremberg, and clinical collaborator on our CLN-978 program, at IFRA 2024 as he discusses T cell engagers in breaking treatment resistance in rheumatoid arthritis.

Cullinan Therapeutics was honored to sponsor and participate in the 2024 Walk to End Lupus Now hosted by?Lupus Foundation of America, Inc. in Boston this weekend! It was an inspiring day filled with hope, community, and a shared commitment to supporting people with lupus. We are proud to be a part of the lupus community and will continue to stand with those affected as we work toward better treatments.

We’re thrilled to share Nadim Ahmed, President and CEO, has been named to the 2024 PharmaVoice 100, which recognizes inspiring leaders in the life sciences industry. ? ? Over the course of his career, Nadim has overseen the launch of several cancer therapies to market and has consistently maintained an unwavering commitment to helping patients and empowering his teams to reach their full potential.? ? Since joining Cullinan Therapeutics in 2021, Nadim has fostered an environment that enables our teams to take decisive action in pursuit of diverse opportunities that push conventional boundaries and accelerate transformative solutions for patients. Over just a two-year period, he built the clinical development infrastructure and advanced five more molecules into the clinic, doubled the size of the company in a volatile market, and expanded our therapeutic area focus from oncology to add autoimmune diseases. A true champion of scientific excellence, Nadim is continuing to lead Cullinan to new heights.? ? Join us in congratulating Nadim on this well-deserved recognition. ???? ? Read more: https://bit.ly/3BETsCE? ? #PharmaVoice100?

What would Dr. Ricardo Grieshaber-Bouyer, Professor of Clinical Systems Immunology and Head of the Clinical Trials Unit at FAU Erlangen-Nuremberg, like the world to look like for a patient with rheumatoid arthritis??? ? Jeff Jones, Chief Medical Officer, recently sat with Dr. Grieshaber-Bouyer to discuss his clinical experience in rheumatic diseases, the potential of T cell engagers in treating autoimmune diseases, and his hopes for breaking through the ceiling of what current therapeutic approaches offer.

Today at 2:30 p.m. ET, Patrick A. Baeuerle, co-founder and Chief Scientific Advisor, will present at Society for Immunotherapy of Cancer (SITC)’s Immuno-Oncology Drug Development Summit.??? ? Known for his contributions to the field of immuno-oncology for leading the development of bispecific T cell engagers, Patrick’s #SITC presentation will focus on T cell engagers for liquid tumors.? ? Click for more details: https://bit.ly/3MGlXC3

The convergence of scientific innovation in #oncology and #immunology is accelerating our opportunities to advance new standards of care for patients with #cancer and #autoimmune diseases. ? ? Hear from Jennifer Michaelson, Chief Scientific Officer, on how Cullinan is applying oncology breakthroughs to research in autoimmune diseases in a panel discussion at the #FierceBiotechSummit. Learn more: https://bit.ly/3ZAdmIP

At #ESMO24, we presented the latest clinical findings from our Phase 2b study of zipalertinib which demonstrated positive results in heavily pretreated patients with non-small cell #LungCancer harboring EGFR exon 20 insertion mutations, who have progressed on or after treatment with amivantamab. With limited treatment options available for these patients, we look forward to advancing our comprehensive development plan for zipalertinib as part of our mission to bring new standards of care to patients. Learn more: https://bit.ly/4e2yk7A

Today at 10:20 AM ET, Nadim Ahmed, President and CEO, and Jeff Jones, Chief Medical Officer, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference in New York, NY.? ? A live webcast and recording will be available here:?https://bit.ly/4bD5WHU #CantorHCC